DARMSTADT (DPA, CONVERSEER) – German pharmaceutical giant Merck has entered into an agreement with US President Donald Trump’s administration to broaden access to its in vitro fertilization (IVF) therapies.
The initiative aims to support over 10 million American women facing fertility challenges, the company said on Thursday.
Under the agreement, Merck’s US and Canadian healthcare division, EMD Serono, will offer Direct-to-Consumer sales of its full IVF therapy portfolio – including Gonal-f, Ovidrel, and Cetrotide – at significantly reduced prices for eligible patients with prescriptions.
When used together in a standard IVF protocol, the therapies will be available at an 84% discount off list prices.
These offerings will be accessible via the TrumpRx.gov platform, launching in January 2026, alongside EMD Serono’s existing and expanded pharmacy networks.
READ ALSO: VW boss Oliver Blume to step down as chief executive of Porsche
Additionally, EMD Serono has reached an agreement with the US secretary of commerce to exempt its pharmaceutical products and ingredients from Section 232 tariffs.
In return, the company will invest in future biopharmaceutical manufacturing and research within the United States.
Merck chief executive Belén Garijo said the company had a strong presence in the US.
“We are committed to working with the US administration to add value over the long term, ensuring that our patients and customers continue to have access to and benefit from the innovations within our portfolio.”
(dpa)
